Italia markets open in 3 hours 55 minutes

Vertex Pharmaceuticals Incorporated (VRTX)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a portafoglio
226,71+8,61 (+3,95%)
Alla chiusura: 1:00PM EST

Vertex Pharmaceuticals Incorporated

50 Northern Avenue
Boston, MA 02210
United States
617 341 6100
http://www.vrtx.com

Settore/iHealthcare
SettoreBiotechnology
Impiegati a tempo pieno3.000

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Jeffrey Marc LeidenExec. Chairman4,88M47,52M1956
Dr. Reshma KewalramaniCEO, Pres & Director2,03M304,26k1973
Mr. Charles F. Wagner Jr.Exec. VP & CFO1,66MN/D1968
Mr. Amit K. SachdevExec. VP & Chief Patient Officer1,41M3,37M1968
Mr. Stuart A. ArbuckleExec. VP & Chief Commercial Officer2,07M2,5M1966
Mr. Paul M. SilvaSr. VP & Corp. Controller833,97k515,17k1966
Dr. David M. AltshulerExec. VP of Global Research & Chief Scientific OfficerN/DN/D1965
Mr. Mike TirozziSVP and Chief Information & Data OfficerN/DN/DN/D
Mr. Michael J. PariniExec. VP & Chief Admin., Legal and Bus. Devel. OfficerN/DN/D1975
Mr. Michael PartridgeSr. VP of Investor RelationsN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2019 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics. The company was founded in 1989 and is headquartered in Boston, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Vertex Pharmaceuticals Incorporated al 1 novembre 2019 è 8. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 9; diritti degli azionisti: 6; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.